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Infl ammatory bowel disease (IBD) is a heterogeneous group of chronic infl ammatory disorders of the gastrointestinal tract with two main distingu-
ishable entities, Crohn’s disease (CD) and ulcerative colitis (UC). IBD-unclassifi ed (IBD-U) is a diagnosis that covers the “grey” zone of diagnostic un-
certainty between UC and CD. Current diagnosis of IBD relies on the clinical, endoscopic, radiological, histological and biochemical features, but this 
approach has shortcomings especially in cases of overlapping symptoms of CD and UC. The need for a diagnostic tool that would improve the con-
ventional methods in IBD diagnosis directed the search towards potential immunological markers, since an aberrant immune response against mi-
crobial or endogenous antigens in a genetically susceptible host seems to be implicated in IBD pathogenesis. The spectrum of antibodies to diff erent 
microbial antigens and autoantibodies associated with IBD is rapidly expanding. Most of these antibodies are associated with CD like anti-glycan 
antibodies: anti-Saccharomices cerevisiae (ASCA) and the recently described anti-laminaribioside (ALCA), anti-chitobioside (ACCA), anti-mannobi-
oside (AMCA), anti-laminarin (anti-L) and anti-chitin (anti-C) antibodies; in addition to other antibodies that target microbial antigens: anti-outer 
membrane porin C (anti-OmpC), anti-Cbir1 fl agellin and anti-I2 antibody. Also, autoantibodies targeting the exocrine pancreas (PAB) were shown to 
be highly specifi c for CD. In contrast, UC has been associated with anti-neutrophil cytoplasmic autoantibodies (pANCA) and antibodies against goblet 
cells (GAB). Current evidence suggests that serologic panels of multiple antibodies are useful in diff erential diagnosis of CD versus UC and can be a 
valuable aid in stratifying patients according to disease phenotype and risk of complications.
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Introduction
The term IBD refers to a chronic and relapsing in-
fl ammatory disorder of the gastrointestinal tract 
(GIT) accompanied by abdominal pain, rectal 
bleeding and malabsorption. It comprises two ma-
jor entities, ulcerative colitis (UC) and Crohn’s dis-
ease (CD). Despite sharing similar clinical features, 
these diseases have signifi cant clinical, endoscopic 
and histopathological diff erences (Table 1) (1-4).
Typically, IBD manifests between adolescence and 
the third decade of life, with approximately 10% of 
cases in individuals younger than 18 years (5). IBD 
diagnosis is based upon the coevaluation of clini-
cal fi ndings, endoscopic, radiological, histological 
and laboratory investigations with the main goal 
of excluding other conditions with similar presen-
tations and defi ning the extent and severity of in-
fl ammation. In the majority of cases, endoscopic 
fi ndings and histological examination of tissue bi-
opsies provides a specifi c diagnosis of UC or CD 
(3,6-8). However, despite all available diagnostic 
methods, approximately 5 to 15% of patients with 
IBD aff ecting the colon are unclassifi able, as they 
present features of both conditions. Such patients 
are diagnosed with indeterminate colitis (IC) or IBD 
unclassifi ed (IBDU), which is considered to be a 
temporary diagnosis since about 80% of these pa-
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Feature Crohn’s disease Ulcerative colitis
Clinical features
Diarrhea Fairly common Very common
Rectal bleeding Fairly common Very common
Sites of involevment
Ileum and colon (ileocolonic region) 50% of patients Never
Ileum 30% of patients Never
Colon 20% of patients Exclusively
Upper parts of GIT Infrequent Never
Endoscopic fi ndings Discontinuous lesions, cobblestoning, 
aphthous and linear ulcerations, strictures
Continous lesions, pseudopolyps
Histologic fi ndings Transmural infl ammation Mucosal/submucosal infl ammation
TABLE 1. The key features of Crohn’s disease and ulcerative colitis.
Antibodies to microbial antigens Autoantibodies
Anti-glycan antibodies (ASCA, 





ASCA - Anti-Saccharomyces cerevisiae antibodies; ACCA - 
antichitobioside carbohydrate antibodies; ALCA - antilaminaribioside 
carbohydrate antibodies; AMCA - anti-mannobioside carbohydrate 
antibodes; Anti-L - anti-laminarin antibodies; Anti-C - anti-chitin 
antibodies; Anti-OmpC - antibody to outer membrane porin 
C; Anti-I2 - antibody to Pseudomonas fl uorescens - associated 
sequence I2; Anti-Cbir1 - antibody to bacterial fl agellin; pANCA - 
anti-neutrophil cytoplasmic antibodies; PAB - antibodies against 
exocrine pancreas; GAB - antibodies to goblet cells.
TABLE 2. Serological markers of IBD.
tients will eventually be diagnosed with either UC 
or CD (2,9,10).
The growing body of evidence suggests that IBD 
evolved as a result of inappropriate and ongoing 
activation of the mucosal immune system driven 
by the commensal luminal microfl ora in a geneti-
cally susceptible host (2,4,11-14). The triggering 
factor for disturbance of the tightly regulated bal-
ance between immune tolerance and defensive 
infl ammatory response to intestinal microbiota is 
yet to be discovered. The serological immune re-
sponse in IBD patients, which includes antibodies 
against the yeast Saccharomyces cerevisiae (ASCA), 
Escherichia coli outer membrane porin C (Omp-C), 
fl agelin (cBir1) and Pseudomonas fl uorescens – as-
sociated sequence I-2 (I2), suggests that commen-
sal fl ora or a dietary antigen is the triggering fac-
tor. On the other hand, the autoimmune concept 
has its base in the autoimmune extraintestinal 
manifestations of IBD (infl ammation of the skin, 
eyes and joints), successful immunosupressive 
therapy and a variety of autoantibodies including 
antineutrophil cytoplasmic antibodies (ANCA), an-
tibodies against exocrine pancreas (PAB) or intesti-
nal goblet cells (GAB) (15-17).
The objective of this review is to give an overview 
of the current knowledge of the serological mark-
ers in IBD with regard to their use in diff erentiating 
IBD from other conditions with similar presenta-
tion, in diff erentiating UC from CD, in disease strat-
ifi cation and prediction and, fi nally, their response 
to therapeutic interventions in IBD.
Serologic markers of IBD
Generally, antibodies related to IBD encompasses 
two main groups: antibodies targeting microbial 
antigens and autoantibodies (Table 2.).
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Anti-glycan antibodies
These antibodies targets cell wall carbohydrate 
epitopes found in microbiota such as yeasts and 
bacteria (18,19). The most prominent member of 
this group of antibodies are anti-Saccharomyces 
cerevisiae antibodies (ASCA). The major antigen 
targeted with ASCA antibodies is the 200 kDa 
phosphopeptidomannan (PPM), a cell wall man-
nan of the common baker’s or brewer’s yeast Sac-
charomyces cerevisiae. The greatest discrimination 
among patients with Crohn’s disease, ulcerative 
colitis, and controls was obtained with the Su1 
strain of S. cerevisiae used in beer brewing and 
mannotetraose was identifi ed as the most impor-
tant polysaccharide epitope within PPM (16,20). 
Regarding the widespread distribution of oligo-
mannosides, three theories have been presented 
in an attempt to explain the mannose-induced im-
munological response. The fi rst theory assumed 
that ASCA antibodies originate from immunization 
by dietary yeasts or yeasts that colonize the diges-
tive tract, as a consequence of increased exposure 
of yeast antigens to immune reactive cells due to 
increased intestinal permeability (20-23). The sec-
ond theory considers the epitopes shared by other 
microorganisms (Mycobacterium species), and the 
third presupposes structural homologies between 
S. cerevisiae oligomannosides and oligomanno-
sides expressed on human glycoconjugates as au-
toantigens or neoautoantigens (20,24). ASCA was 
shown to have a high specifi city for CD, and both 
IgA and IgG antibodies are formed. Methods used 
for the detection of these antibodies are indirect 
immunofl uorescence (IIF) using smears of Saccha-
romyces cerevisiae or standardized enzyme linked 
immunosorbent (ELISA) assays with an antigen de-
rived from disrupted or boiled S. cerevisiae and 
phosphopeptidomannan purifi ed from the cell wall 
(gASCA assay) coated on microtiter plates (25-30).
In an attempt to identify novel antibodies associ-
ated with infl ammatory bowel disease, Dotan et al. 
(18) profi led sugar-binding antibodies from the se-
rum of patients with diagnosed CD or UC using 
glycan array technology and ELISA. The newly 
identifi ed antibodies were antilaminaribioside car-
bohydrate IgG antibodies (ALCA), antichitobioside 
carbohydrate IgA antibodies (ACCA) and anti-man-
nobioside carbohydrate IgG antibodes (AMCA) 
(18,31,32). Laminaribioside is a building block of 
the glucose-based glycan laminarin, while chitobi-
oside is a building block of the N-acetyl-glu-
cosamine-based glycan chitin. Both laminaribio-
side and chitobioside, as well as mannose and 
mannan, are components of the cell walls of mi-
croorganisms such as bacteria, fungi and yeast and 
are capable of stimulating the immune system, 
specifi cally innate immunity (33). The most recent-
ly discovered members of the anti-glycan family of 
antibodies in IBD were anti-laminarin (anti-L) IgA 
antibodies and anti-chitin (anti-C) IgA antibodies 
(34). Similarly to ASCA, these antibodies have prov-
en to be specifi c for CD, though with signifi cantly 
lower sensitivity.
Antibody to outer membrane porin (anti-OmpC)
OmpC is an outer membrane porin C isolated from 
Escherichia coli. Originally, this protein was identi-
fi ed as a pANCA cross-reactive antigen using the 
library of colonic bacteria (35). The ELISA assay 
demonstrated an excessive secretion of IgA anti-
OmpC antibodies in CD patients (36,37).
Antibody to Pseudomonas fl uorescens - asso-
ciated sequence I2 (anti-I2)
In 2000, the novel DNA sequence (I2) with homol-
ogy to the ptxR and tetR bacterial transcription 
factor family was isolated from CD colonic lesional 
mucosa, suggesting that the microorganism ex-
pressing the I2 gene product may be related to CD 
pathogenesis (38). This bacterial sequence has 
been shown to derive from Pseudomonas fl uores-
cens (39). An ELISA assay showed frequent immu-
noglobulin A seroreactivity in CD as opposed to 
UC or other infl ammatory enteric diseases and 
healthy individuals (37,38).
Antibody to bacterial fl agellin CBir1
(anti-CBir1)
Among bacterial antigens, fl agellin is an interest-
ing candidate to play a role in mucosal immune re-
sponses because it is a common bacterial antigen 
present on most motile bacteria in the gut and is 
highly antigenic. Multiple strains of colitic mice 
had elevated serum anti-fl agellin IgG2a responses, 
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and fl agellin CBir1 has been identifi ed as an immu-
nodominant colitogenic antigen. In line with this, it 
has high anti-CBir1 IgG reactivity in human CD pa-
tient sera, as detected with the ELISA assay, and only 
minor reactivity in the sera of patients with UC or 
other infl ammatory GIT diseases. CBir1 fl agellin is 
most closely related to the fl agellins of bacteria in 
the genera Butyrivibrio, Rosburia, Thermotoga, and 
Clostridium and fall within the Clostridium subphy-
lum XIVa cluster of Gram-positive bacteria (40).
Anti-neutrophil cytoplasmic antibodies (ANCA)
ANCAs are classically associated with small-vessel 
systemic vasculitis such as Wegener granulomato-
sis, Churg-Strauss syndrome, microscopic poly-
angiitis and its renal-limited variant (pauci-im-
mune necrotizing and crescentic glomerulone-
phritis), where their measurement is used in the 
purposes of diagnosis, prognosis and in monitor-
ing of infl ammatory activity (41). In vasculitis, this 
heterogenous family of antibodies targets diff er-
ent proteins, mainly located in the azurophilic 
granules of neutrophils and in lysosomes of mono-
cytes. According to the International Consensus 
Statement (41), ANCAs are screened by indirect im-
munofl uorescence (IIF) on normal peripheral 
blood neutrophils where two main types of fl uo-
rescence pattern are obtained: cytoplasmic granu-
lar with accentuation between nuclear lobes (cAN-
CA) and fi ne homogenous, diff use rim-like staining 
of the perinuclear cytoplasm (or rim-accentuated 
fl uorescence of the nuclei) designated as the pAN-
CA pattern. The major ANCA antigen targets in in-
fl ammatory vasculitides are proteinase-3, mainly 
displaying cANCA pattern and myeloperoxidase 
associated with the pANCA pattern (41-43).
The distinct subset of ANCA associated with UC 
was fi rst reported in 1990 (44,45). The pattern of 
staining on IIF exhibited broad inhomogeneous 
rim-like staining of the nuclear periphery, diff erent 
from classical pANCA and was designated as atypi-
cal p-ANCA. Various target antigens of atypical 
pANCA have been intensively studied in IBD pa-
tients. These studies included proteins located in 
the granules of the neutrophils and monocytes 
such as: serine proteases cathepsin G and elastase, 
hydrolase β-glucuronidase, iron-binding protein 
lactoferrin and the natural antibiotic bactericidal 
permeability increasing protein (BPI); cytoplasmic 
proteins such as α-enolase and catalase; proteins 
distributed in the cytoplasm and nuclei of eukary-
otic cells: high-mobility group of non-histone 
chromosomal proteins (HMG-1 and HMG-2), and fi -
nally proteins located in the nuclei, such as histone 
H1 (25,27). Overall, most studies supported the 
conclusion that IBD-associated ANCA specifi c anti-
gens are not located within neutrophil granulas 
but rather within the nuclei. The immunoelectron 
microscopy fi nding of UC-associated pANCA reac-
tivity localized over chromatin concentrated to-
ward the periphery of the nuclei supports this the-
sis (46). However, UC sera did not react with dou-
ble-stranded DNA. Vidrich et al. (47) demonstrated 
the loss of the UC-related pANCA staining pattern 
after digestion of substrate cells with DNAse, sug-
gesting that the epitope recognized by this subset 
of antibodies is a protein-DNA complex or that the 
presence of intact DNA is necessary to maintain 
the integrity of the epitope. It is likely that the tar-
get antigen for UC-related atypical pANCA is a 
complex conformational epitope which comprises 
the previously reported nuclear proteins histone 
H1, HMG-1 and HMG-2. Since the target antigen 
for UC-associated pANCA is yet unrecognized, sen-
sitive and specifi c solid-phase methods cannot be 
developed, and therefore IIF on normal peripheral 
blood neutrophils is still the most commonly em-
ployed method in use. Detection of DNase I - sen-
sitive pANCA antibody is more specifi c for UC in 
diff erentiation from similar pANCA patterns in au-
toimmune liver diseases. Recently, lactoferrin was 
suggested as a major pANCA target in UC but it 
has to be bound to DNA to present epitope rele-
vant for the reaction with the autoantibodies. Use 
of the lactoferrin reconstituted (LFR) granulocytes 
(granulocytes stripped of pANCA targets and then 
reconstituted with human lactoferrin) as a sub-
strate in addition to standard ethanol-fi xed granu-
locytes raised the sensitivity of the IIF assay from 
71.8% to 87.2% (48).
Antibodies against exocrine pancreas (PAB)
These antibodies were fi rst described in 1987 by 
Stöcker et al. (49) who tested sera of patients with 
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CD and UC for autoantibodies by the IIF method 
using 19 diff erent human tissues as antigenic sub-
strates. They demonstrated that autoantibodies 
against exocrine pancreas (PAB) were found al-
most exclusively in CD patients (although with 
rather low sensitivity) and suggested that this spe-
cifi c autoantigen is a component of normal pan-
creatic juice. In the IIF assay on sections of human 
or primate pancreatic tissue, PAB antibodies stain 
diff erent structures of the exocrine pancreas and 
are divided into two subtypes accordingly: sub-
type I with a typical, extracellular, drop-like stain-
ing pattern in the acinar lumen of pancreatic tissue 
sections, and subtype II with speckled staining of 
the cytoplasm of pancreatic acinar cells (50). Re-
cently, the major zymogen granule membrane 
glycoprotein (GP2), a glycosylphosphatidylinositol 
(GPI)-anchored protein of the pancreatic acinar 
cells was identifi ed as the autoantigen of PAB in 
CD (51). Upon hormonal or neuronal stimulation of 
the pancreas, GP2 is transported to the apical com-
partment of acinar cells, from which it is released, 
together with zymogens, into the pancreatic duct. 
The two obtained fl uorescence patterns of PAB on 
pancreatic tissue are consistent with the localiza-
tion of GP2. In addition to pancreatic acinar cells, 
M cell-specifi c expression of GP2 in humans and 
mice was also seen among the intestinal epitheli-
um (52,53) The characteristic of the M-cells as spe-
cialized epithelial cells of mucosa-associated lym-
phoid tissues (Peyer’s patches) is their role in the 
transport of antigens from the lumen to the cells 
of the immune system (54). It was found that the 
GP2 expressed on M cells serves as an uptake re-
ceptor for a subset of commensal and pathogenic 
bacteria (53). Bearing in mind that Peyers patches 
are abundant in the distal part of the ileum, the 
predominant site of infl ammatory onset in CD, 
Roggenbuck et al. (51) demonstrated GP2 expres-
sion at mRNA and protein levels in colon biopsies 
from patients with CD at a signifi cantly higher lev-
el than in UC colon biopsies. This observation sup-
ports the hypothesis of a direct involvement of 
anti-GP2 in CD pathophysiology, rather than being 
merely an epiphenomenon as an antibody target-
ing non-intestinal antigen.
Antibodies to goblet cells (GAB)
Intestinal epithelial cells represent a physical barri-
er against the excessive entry of bacteria and other 
antigens from the intestinal lumen into the circula-
tion. Goblet cells, as specialized intestinal epitheli-
al cells, regulate the production of mucus and fac-
tors that contribute to epithelial repair and regula-
tion of infl ammation (4). GAB have been detected 
primarily in adult UC patients with prevalence var-
ying from 15% to 46.6% while in CD patients ob-
served prevalence of GAB showed even wider 
range from 1.4% to 33% (15,49,55,56). Obtained 
diff erences in GAB prevalence are likely attributed 
to methodological diff erences, such as the use of 
diff erent origin of antigenic substrate for IIF: hu-
man or monkey intestinal tissue, rarely rat jejunum 
or human colonic cancer cell line HT29-18-N2, 
which diff erentiates into intestinal goblet cells. Tis-
sue substrates are associated with problematic re-
producibility due to the natural fl uctuations of tis-
sue quality. The next sources of variability in the 
obtained results lie in the evaluation of fl uores-
cence patterns on IIF. Beside the IIF test, the ELISA 
assay using the HT29-18-N2 cell line assay is also in 
use for GAB detection (55).
Clinical usefulness of serological 
investigation of IBD
The main concerns regarding clinical usefulness of 
serological markers in IBD refers to: a) their effi  -
ciency in distinguishing IBD from other diseases 
with similar clinical presentation and in distin-
guishing subtypes of IBD (ulcerative colitis from 
Crohn’s disease), b) their prognostic value in strati-
fying disease phenotypes, and c) monitoring dis-
ease activity and refl ecting the response to thera-
peutic intervention.
Serological investigation for IBD diagnostic 
purposes
Use of serological markers in distinguishing IBD 
from other non-IBD gastrointestinal diseases
Currently, diagnosis of IBD is based on a combina-
tion of clinical, radiological, endoscopic and histo-
logical studies and, in most cases, the diagnosis 
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can be made with high certainty. Assessment of 
the currently known IBD-associated antibodies has 
not surpassed the diagnostic accuracy of the pre-
viously mentioned conventional methods, mainly 
due to their limited sensitivity (Table 3) (15,19,26,27, 
29,33,55,56-59).
A positive test result for any individual antibody, 
even those with highest sensitivity like pANCA or 
ASCA, only modestly infl uences the pretest/post-
test probability in distinguishing IBD from other 
GIT disorders with similar clinical presentation, 
while a negative test result has no clinical value. 
Although most studies have confi rmed the high 
specifi city of IBD-associated antibodies (75–99%), 
caution should be taken in considering the control 
groups of non-IBD GIT disorders that mainly in-
cluded irritable bowel syndrome, infectious colitis 
or functional gut disorders (26). Namely, ASCA that 
was considered as a highly CD-specifi c antibody 
was observed in 30% to even 59% of patients with 
celiac disease prior introducing the gluten-free 
diet. ASCA antibodies were more often of the IgG 
class and were, unlike the ASCA-IgA, insensitive to 
gluten withdrawal (60,61). Another highly CD-spe-
cifi c antibody, PAB, showed a frequency of 22.3% 
in celiac patients at diagnosis (more often IgA 
class), and positivity demonstrated a tendency to 
be lower in patients on a strict gluten-free diet 
(56). This observation suggests that the presence 
of ASCA or PAB may be a marker for increased per-
meability of the small bowel and autoimmunity in-
stead of a specifi c IBD (CD) marker.
Therefore, at the present, assessment of serologi-
cal markers are not suitable for screening for IBD in 
patients with gastrointestinal symptoms, but rath-
er as assistance in cases of a diagnostic dilemma.
The variation in the prevalence of individual sero-
logical markers across studies could be explained 
by diff erences in the methods used. For example, 
pANCA have been determined with standardized 
IIF on ethanol fi xed neutrophils from healthy do-
nors, or with fi xed granulocytes ELISA, or using 
ELISA followed with IIF for ANCA-ELISA positive 
samples. Some studies were performed with IIF in-
cluding the step with DNase I digestion of neu-
trophils. Variation in the sensitivity of pANCA as-
Antibody Immunoglobulin class
Prevalence (%)
CD UC other GIT disorders Healthy
ASCA IgA and/or IgG 29–71 0–29 0–23 (37.9)* 0–16
ACCA IgA 8–25 5–7 3–20 0.5–12
ALCA IgG 17.7–27 3–8 9 2
AMCA IgG 12–28 7 8 9
Anti-L IgA 11–26 3–7 23 1–10
Anti-C IgA 10–25 2–10 11 2–12
Anti-OmpC IgA 24–55 2–24 5–11 5–20
Anti-I2 IgA 38–60 2–10 19 5–15
Anti-Cbir1 IgG 50–56 <6 14 8
PAB IgA and IgG 26–39 0–22.7 0–11.5 (22.3)* 0–8
GAB IgA and IgG 1.4–33 15.4–46.6 0–9.3 0
pANCA IgG 2–38 24–85 8 0–8
* prevalence in active celiac disease. CD - Crohn’s disease; UC - ulcerative colitis; ASCA - Anti-Saccharomyces cerevisiae antibodies; ACCA - 
antichitobioside carbohydrate antibodies; ALCA - antilaminaribioside carbohydrate antibodies; AMCA - anti-mannobioside carbohydrate 
antibodes; Anti-L - anti-laminarin antibodies; Anti-C - anti-chitin antibodies; Anti-OmpC - antibody to outer membrane porin C; Anti-I2 
- antibody to Pseudomonas fl uorescens - associated sequence I2; Anti-Cbir1 - antibody to bacterial fl agellin; PAB - antibodies against 
exocrine pancreas; GAB - antibodies to goblet cells; pANCA - anti-neutrophil cytoplasmic antibodies.
TABLE 3. Prevalence of individual serological markers in patients with IBD, non-IBD GIT disorders and healthy individuals (15,19,26, 
27,29,33,55-59).
Biochemia Medica 2013;23(1):28–42  http://dx.doi.org/10.11613/BM.2013.006
34
Tesija Kuna A. Serological markers in IBD
says from 0–63% in UC samples across fi ve diff er-
ent laboratories suggests that these assays obvi-
ously do not detect the same spectrum of antigens 
(28). Also, considerable lack of agreement exists 
within the same methodology due to diff erences 
in antigen preparation and quality, cut-off  values 
based on the receiver operating curve, diff erences 
in evaluation of fl uorescence patterns for IIF meth-
ods, cut-off  titer or the origin of the substrate used 
for IIF.
Distinguishing CD from UC 
The heterogeneity within the IBD group of disor-
ders infl uences the clinical presentation with over-
lapping symptoms of CD and UC. In up to 15% of 
cases, no diff erentiation into a particular IBD sub-
type can be made, giving rise to a diagnosis of 
IBD-unclassifi ed (IBD-U) or previously known as in-
determined colitis (IC). Diff erentiation into either 
of the IBD subtypes in the early phase of the dis-
ease has an infl uence on the tailoring of drug ther-
apy. According to retrospective database analysis 
of 250 children diagnosed with IBD, IBD-U appears 
to have a higher prevalence among paediatric pa-
tients (up to 29.6%) and is associated with early 
disease onset and rapidly progresses to pancolitis 
(62). In the same study, 66.2% patients maintained 
their diagnosis of IBD-U after a mean follow-up of 
7 years, which favours the hypothesis of some in-
vestigators that IBD-U is a unique disease pheno-
type within the IBD group, with more a extensive 
disease, more severe clinical course and higher 
rate of complications. Paediatric IBD patients com-
prise a particular population in whom non-inva-
sive testing is desirable and who would benefi t the 
most from the early proper therapeutic approach. 
As the specifi city of serological markers exceeds 
their sensitivity, serological profi les can be useful 
in the diff erentiation of IBD subtypes (62,63).
Most of the data pertaining to the usefulness of 
serological markers in distinguishing CD from UC 
refer to the ASCA and pANCA antibodies, while 
fewer data are available for other anti-glycan anti-
bodies, anti-I2, anti-Omp-C, anti-Cbir1, PAB or GAB. 
Overall, ASCA has the best combined sensitivity 
and specifi city for CD and pANCA for UC. Most 
other investigated serological markers are specifi c 
for CD, with the exception of GAB. Table 4. summa-
rizes the data on diagnostic accuracy of individual 
and combined antibodies in the diff erential diag-
nosis of of CD and UC (10,15,26-30,56,64-66).
The general opinion is that combined testing in-
stead of individual antibodies is more useful in ob-
taining a diff erential diagnosis of CD versus UC. 
Profi le ASCA+/pANCA- increases specifi city and 
positive predictive value (PPV) for diagnosis of CD 
comparing to ASCA+ as isolated result. In the same 
manner, the reverse profi le pANCA+/ASCA- was 
shown to have a higher specifi city and PPV for di-
agnosis of UC than pANCA+ alone (26-30). Profi le 
pANCA-/ASCA- was found to have a strong posi-
tive correlation with IBD-U diagnosis. Prospective 
study of IBD-U patients revealed that half of the 
patients had pANCA-/ASCA- seroprofi le and the 
vast majority of them did not change the initial di-
agnosis after 6 years. Therefore, pANCA-/ASCA- 
seems to be the serological marker closely associ-
ated with IBD-U as a separate disease entity (30,63).
Recent study assessed the reactivity of seven anti-
glycan antibodies in a large cohort of 818 IBD pa-
tients, including gASCA IgA and IgG (gASCA is an 
improved ASCA assay based on immobilized puri-
fi ed mannan polysaccharide), ACCA, ALCA, AMCA, 
anti-L and anti-C (34). Within the CD patient popu-
lation, 73% were positive for ≥ 1 anti-glycan anti-
body. All anti-glycan markers were specifi c for CD 
and were signifi cantly more prevalent in CD than 
in UC. The most effi  cient discrimination between 
CD and UC was achieved by the addition of anti-L 
and anti-C to gASCA/pANCA panel while adding 
of anti-L to the same panel improved diff erentia-
tion of colonic CD from UC.
Diagnostic accuracy for CD versus UC of the gASCA 
and ALCA antibodies was fi nd out to be similar be-
tween adult and paediatric IBD cohorts, while dis-
crepancies were found for AMCA and ACCA. In 
paediatric population, both serologic markers 
showed signifi cantly higher specifi city, while 
AMCA showed signifi cantly lower sensitivity com-
pared to adults (33).
The importance of combined testing was pointed 
out by the fi nding that about one third of ASCA 
negative CD patients may be positive for at least 
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Diagnosis Antibody Sensitivity (%) Specifi city (%) PPV NPV
CD
ASCA + 37–72 82–100 87–95 36–68
pANCA - 52 91 85 65
ACCA 9–21 84–97 78–87 24–52
ALCA 15–26 92–96 78–90 25–53
AMCA 12–28 82–97 65–92 25–52
Anti-C 10–25 90–98 87–88 29–39
Anti-L 18–26 93–97 90–91 30–40
Anti-OmpC 20–55 81–88 83 25
Anti-I2 42 76 NR NR
PAB 22–46 77–100 69–100 48–75
ASCA+/pANCA- 46–64 92–99 86–97 44–82
PAB+/ANCA- 22–42 98–100 87–100 48–74
PAB+/ASCA+/pANCA- 16–34 97–100 100 66–72
UC
pANCA 50–71 75–98 74–95 49–84
pANCA+/ASCA- 42–58 81–100 93–100 43
GAB 12*–46 98 75–93 70–74
pANCA or GAB+/PAB- 82 98 96 89
* in pediatric population. PPV - positive predictive value; NPV - negative predictive value; ASCA - Anti-Saccharomyces cerevisiae 
antibodies; pANCA - anti-neutrophil cytoplasmic antibodies; ACCA - antichitobioside carbohydrate antibodies; ALCA - antilaminaribioside 
carbohydrate antibodies; AMCA - anti-mannobioside carbohydrate antibodes; Anti-C - anti-chitin antibodies; Anti-L - anti-laminarin 
antibodies, Anti-OmpC - antibody to outer membrane porin C; Anti-I2 - antibody to Pseudomonas fl uorescens - associated sequence I2, 
PAB - antibodies against exocrine pancreas; GAB - antibodies to goblet cells; NR - not reported.
TABLE 4. Diagnostic accuracy of individual serological markers and their combinations in diff erential diagnosis of CD and UC (10,15,26-
30,56,64-66).
one of the previously mentioned anti-glycan anti-
bodies (67).
Similarly, anti-CBir1 were positive in about half of 
ASCA-negative adult CD patients while the addi-
tion of the anti-CBir1 assay to the ASCA, pANCA 
and anti-OmpC panel halved the number of sero-
logically negative paediatric CD patients (68,69).
PAB was confi rmed as a highly specifi c marker of 
CD in several studies, but with low sensitivity 
(15,29,65). Therefore, the use of PAB in combina-
tion with pANCA and ASCA was suggested, partic-
ularly in the diff erentiation between isolated co-
lonic CD and UC where the clinical diffi  culty lies in 
the diff erentiation between CD and UC. In another 
study, authors concluded that PAB detection could 
be useful only in clinically highly suspected pa-
tients without circulating ASCA, since they found 
PAB positivity in 14% of CD patients that were neg-
ative for ASCA (29). Several studies, however, 
showed lower specifi city of PAB in distinguishing 
CD from UC both in adult and paediatric patients 
(56,63,66).
In majority of reports, GAB was confi rmed as high-
ly specifi c serological marker in distinguishing UC 
from CD, but due to the low sensitivity (especially 
in paediatric population, 12%) it is poorly usable in 
diff erential diagnosis of IBD subtypes, both in 
adults and children (15,56,65,66,70).
However, in a recent study by Homsak et al. (15), 
the combination of positive pANCA or GAB with 
negative PAB managed to detect the majority of 
UC patients.
In summary, testing for isolated antibody is of lim-
ited value in diff erential diagnosis of IBD subtypes, 
while the combined testing of several antibodies 
(serologic panels) signifi cantly improves specifi city 
Biochemia Medica 2013;23(1):28–42  http://dx.doi.org/10.11613/BM.2013.006
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and PPV for certain IBD subtype. Furthermore, 
widening panel of antibodies can also improve the 
sensitivity. However, result of serological testing is 
not decisive but is an adjunctive tool in patients in 
whom all other clinical features does not allow a 
distinction between CD and UC.
Use of serological testing in disease
phenotype stratifi cation
The heterogenic nature of both CD and UC is re-
fl ected in the diff erent phenotypes of the disease, 
according to location, clinical course and activity 
or behaviour patterns, and response to treatment 
within each IBD subtype. An ability to stratify IBD 
subtypes by the risk for disease progression and 
complications would most certainly improve over-
all disease outcomes through an early decision of 
the most appropriate treatment option available.
In addition to contributing to an improved IBD di-
agnosis, there is mounting evidence of a link be-
tween serum immune reactivity and specifi c clini-
cal phenotypes in IBD.
In CD, disease extent can evolve with time from a 
non-stricturing, non-fi stulizing, infl ammatory phe-
notype to a more severe stricturing (fi brostenotic) 
or penetrating (with internal fi stulae, fi stulizing) 
phenotype (71). Numerous studies have examined 
the presence of diff erent IBD-related antibodies and 
disease behaviour (9,19,26,64,68,69,72-80). Positive 
association of the most of the anti-microbial, espe-
cially anti-glycan antibodies with more complicated 
CD phenotype and a higher frequency of Crohn’s 
disease-related abdominal surgery has been con-
sistently demonstrated (Table 5). It is important to 
emphasize that this association becomes stronger 
with increasing diversity (multiple antibodies) and 
magnitude (higher titers) of the serologic response.
Antibody CD phenotype characteristics Reference
ASCA (ASCA+/pANCA-) disease located in small bowell (or ileocolonic)
stricturing and/or penetrating
higher risk for IBD-related surgical interventions
early disease onset
9, 19, 26, 64, 72–76, 79, 80
pANCA (pANCA+/ASCA-) benign (UC-like) with colonic involvment, non-stricturing, 
non-penetrating
9, 72, 77
anti-CBir1 disease located in small bowell, stricturing and/or penetrating
early disease onset
68, 69, 81
anti-OmpC disease located in small bowell, stricturing and/or penetrating
higher risk for IBD-related surgical interventions
78 - 80
anti-I2 higher risk for stricturing phenotype
higher risk for IBD-related surgical interventions
79
AMCA stricturing and/or penetrating
higher risk for IBD-related surgical interventions,
early disease onset
19, 67, 78, 80
ACCA stricturing and/or penetrating
higher risk for IBD-related surgical interventions
19, 78, 80
ALCA stricturing and/or penetrating
higher risk for IBD-related surgical interventions
78, 80
anti-L stricturing and/or penetrating
strong association with IBD-related surgical interventions
19, 64
anti-C strong association with IBD-related surgery 64
ASCA - Anti-Saccharomyces cerevisiae antibodies; pANCA - anti-neutrophil cytoplasmic antibodies; Anti-Cbir1 - antibody to bacterial 
fl agellin; Anti-OmpC - antibody to outer membrane porin C; Anti-I2 - antibody to Pseudomonas fl uorescens - associated sequence I2, AMCA 
- anti-mannobioside carbohydrate antibodes; ACCA - antichitobioside carbohydrate antibodies; ALCA - antilaminaribioside carbohydrate 
antibodies; Anti-L - anti-laminarin antibodies, Anti-C - anti-chitin antibodies.
Table 5. Association of serological markers with CD phenotype.
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Similar results were obtained in the paediatric 
population. Dubinsky et al. (81) evaluated associa-
tions between anti-I2, anti-OmpC, anti-CBir1 and 
ASCA immune response and clinical phenotype in 
196 paediatric CD patients. Increased frequency of 
internal penetrating and/or stricturing disease 
with increasing diversity of immune response was 
demonstrated, with the highest odds in patients 
positive for all four antibodies. Also, patients posi-
tive for ≥1 antibody progressed to a complicated 
disease faster than those negative for all antibod-
ies. These results were further confi rmed for the 
same panel of antibodies in a later study per-
formed on a 796 paediatric CD patients (82).
Data on the association of PAB with the CD pheno-
type are somewhat confl icting. In the Eastern Eu-
ropean IBD cohort, antibody response to PAB was 
proven to be associated with complicated disease 
phenotype and extraintestinal manifestations. The 
presence of PAB was associated with perianal dis-
ease and extraintestinal manifestations such as ar-
thritis, ocular or cutaneous manifestations. Also, 
the presence of PAB IgA antibodies was associated 
with penetrating disease behaviour (56). On the 
contrary, in the study of Joosens et al. (57) both 
PAB patterns were negatively associated with stric-
turing disease behaviour of CD. In the study con-
ducted on Caucasian and Chinese IBD populations, 
PAB expression was not associated with stricturing 
or perforating CD, while in another study, the small 
diff erences in PAB prevalence in CD subtypes do 
not suggest that PAB detection is useful in the dis-
crimination of CD phenotypes (65,83). In a study of 
PAB and GAB antibodies in paediatric IBD patients, 
there was a lack of correlation with the clinical 
phenotype (66).
In contrast to CD, UC has a less heterogeneous dis-
ease behaviour but can evolve into a more aggres-
sive phenotype with regard to a higher number of 
surgical interventions, moderate to severe disease 
activity or larger disease extent. In the study per-
formed on 366 IBD patients, no relation of pANCA 
in UC patients or in CD patients was found with 
disease activity, duration of illness, location, dis-
ease extent, previous bowel operations or medical 
treatment (84). In another study, a tendency of 
higher prevalence of pANCA+ or pANCA+/ASCA- 
reactivity in severe UC compared to remission cas-
es according to the Montreal classifi cation was 
demonstrated, though this diff erence was not sta-
tistically signifi cant. The pANCA-/ASCA- pattern 
was observed less often in active UC when com-
pared to remission phase although with border-
line signifi cance (9).
In other UC cohorts, pANCA expression was signif-
icantly associated with a higher relapse rate, more 
aggressive disease course requiring early colecto-
my or with the treatment-resistant left-sided dis-
ease (85-87). A possible association between pAN-
CA and relative resistance to medical therapy in 
UC patients was also recently documented, with 
negative pANCA status as an independent positive 
predictor for response to treatment with infl iximab 
(88).
Recent studies indicated that serological respons-
es may identify patients with higher risk for post-
operative complications in patients with UC or 
IBD-U. Patients who were pANCA-/ASCA+ were 
shown to have an increased risk for the develop-
ment of fi stulas after surgical intervention com-
pared to patients who were pANCA+/ASCA-, and 
were also more likely to have their diagnosis 
changed postoperatively to CD (89). Another study 
confi rmed preoperative ASCA-IgA seropositivity 
as a predictor of postoperative CD diagnosis in UC 
and IBD-U patients (90). There is an indication that 
high levels of pANCA prior to colectomy is signifi -
cantly associated with the development of post-
operative complications in UC patients (91).
In summary, an assessment of serological markers 
is useful as a predictor of complicated disease be-
haviour in CD or in predicting postoperative com-
plications in UC or IBD-U patients. The presence of 
multiple antibodies and the magnitude of the im-
munological response appear to be the strongest 
predictors of disease progression.
Use of serologic markers in monitoring disease 
activity and response to drug therapy
According to the available data, there is no use of 
serial measurement of IBD serological markers, in-
cluding ASCA, ALCA, ACCA, anti-OmpC or pANCA 
in monitoring disease activity (26,27,92).
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Regarding the association with response to thera-
py, there was no relationship between ASCA or 
pANCA and response to therapy in a study con-
ducted on 279 CD patients before starting anti-
TNF therapy (infl iximab). Although lower response 
rates were observed for patients with refractory 
intestinal disease carrying the pANCA+/ASCA- 
combination, this fi nding lacked signifi cance (P = 
0.067) (93). Possible association of pANCA with rel-
ative resistance to medical therapy was further 
documented in a study by Sandborn et al. (87) who 
found an increased frequency of pANCA in treat-
ment-resistant left-sided ulcerative colitis. The re-
port of a negative pANCA status as an independ-
ent positive predictor for response to therapy with 
infl iximab in UC patients supports this (88). Other 
studies have not found an association between 
ALCA, ACCA, AMCA, anti-OmpC, anti-I2 or pANCA 
and treatment in CD (26).
Other aspects of IBD serological markers
Prevalence and diagnostic value of IBD serological 
markers have shown signifi cant variation among 
diff erent ethnic or geographic population. For ex-
ample, in Chinese, Japanese and Iranian CD pa-
tients ASCA was shown to be less sensitive com-
paring to Caucasians. On the other hand, studies 
conducted on Tunisian, Korean and Brasilian pa-
tients yielded prevalences comparable to Cauca-
sian CD patients The prevalence of pANCA was 
found to be lower in Chinese, Japanese, Korean, 
Thai and Romanian patients with UC but higher in 
Mexican-American compared to Caucasian UC pa-
tients (26,32). Therefore, these data suggest that 
ethnic background should be considered when 
applying IBD serological markers in clinical prac-
tice.
Family studies indicated ASCA as potential sub-
clinical biomarker for population in risk for CD, as it 
has been reported that this antibody is present 
with signifi cantly higher frequency (20-25%) in un-
aff ected fi rst-degree relatives of CD patients, as 
compared to general healthy population (0-10%) 
(94,95). Furthermore, in the retrospective study, 
ASCA reactivity was found at a median of 38 
months before clinical diagnosis in 32% of CD pa-
tients (96). In contrast to ASCA, PAB seems to rarely 
occur in family members of patients with Crohn’s 
disease (50).
pANCA was not proven as a marker of increased 
susceptibility for disease in fi rst-degree relatives of 
patients with UC (26). Recent study assessed risk 
factors for CD in multicase families and a cumula-
tive eff ect of number of fi rst-degree aff ected rela-
tives, and number of positive antimicrobial anti-
bodies (ASCA, AMCA, ALCA, ACCA, anti-OmpC, 
anti-CBir1, Anti-I2) was found (97).
An interesting aspect of IBD-related serologic re-
sponse is their possible role in bridging the genet-
ic susceptibility and clinical disease. Several stud-
ies investigated the association of serological mark-
ers with IBD-susceptible gene mutations (26,98). In 
spite of some inconsistency, more studies found 
ASCA frequency signifi cantly associated with great-
er frequency of mutant NOD2/CARD15 alleles and 
also the genotype-seroreactivity synergism in pre-
dicting complicated CD phenotypes (33,59, 72,99). 
In accordance with this, it is reported that associa-
tion of other anti-glycan antibodies (ALCA, AMCA, 
ACCA and ASCA) with NOD/CARD15 mutations in a 
dose-eff ect manner is found where more mutations 
were associated with higher seroreactivity (78,80).
Conclusions
The current diagnostic approach based upon clini-
cal, endoscopic, histological, radiological and bio-
chemical criteria provides a reliable diagnosis in 
the majority of cases of IBD over other GIT disor-
ders that share similar clinical presentation, as well 
as diff erentiation into IBD-subtypes, CD or UC. 
However, there are certain cases where a signifi -
cant overlap is present in the results of conven-
tional diagnostic tests, thereby makes diff erentia-
tion of these two subtypes diffi  cult. It is this par-
ticular point in the diagnostic algorithm of IBD 
where serological testing has the greatest benefi t. 
Due to their lack of sensitivity, serological markers 
are not advisable for use in the diagnosis of IBD 
but rather in diff erentiating CD from UC, particu-
larly with the use of a wide panel of antibodies. Ac-
cording to the growing evidence of an association 
between the magnitude of serological immune re-
activity and specifi c clinical phenotypes, the most 
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important clinical utility of serological markers 
could be in stratifying patients according to risk 
for aggressive disease phenotype or postoperative 
complications. Such a “risk score” that would inte-
grate markers of immune response, genetic mark-
ers and clinical characteristics might enable the 
application of personally-tailored therapeutic 
strategies and better surveillance of patients at 
risk. At the current time, there is insuffi  cient evi-
dence of usefulness of serological markers in mon-
itoring the treatment of IBD patients.
Potential confl ict of interest
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